Perspective Therapeutics (NYSEAMERICAN:CATX) Director Robert Williamson III Buys 15,000 Shares of Company Stock

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) Director Robert Williamson III acquired 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 18th. The stock was purchased at an average cost of $0.80 per share, for a total transaction of $12,000.00. Following the acquisition, the director owned 68,473 shares in the company, valued at approximately $54,778.40. This trade represents a 28.05% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link.

Perspective Therapeutics Stock Up 0.5%

Shares of NYSEAMERICAN:CATX opened at $0.78 on Friday. The company’s 50-day moving average price is $1.94 and its 200 day moving average price is $3.38. Perspective Therapeutics, Inc. has a fifty-two week low of $0.73 and a fifty-two week high of $6.16. The company has a current ratio of 5.18, a quick ratio of 5.18 and a debt-to-equity ratio of 0.01.

Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). Perspective Therapeutics had a negative net margin of 55,866.82% and a negative return on equity of 42.25%. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. On average, research analysts predict that Perspective Therapeutics, Inc. will post -1.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CATX has been the subject of several analyst reports. BTIG Research reiterated a “buy” rating on shares of Perspective Therapeutics in a research report on Monday, October 26th. BMO Capital Markets reissued an “outperform” rating on shares of Perspective Therapeutics in a report on Friday, October 30th. Piper Sandler lowered their target price on Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. Wedbush reaffirmed an “outperform” rating and set a $7.00 target price (down from $9.00) on shares of Perspective Therapeutics in a research note on Tuesday, November 10th. Finally, Bank of America reduced their price target on Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating for the company in a research report on Friday, August 14th. Nine investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.10.

Read Our Latest Research Report on CATX

Institutional Trading of Perspective Therapeutics

Institutional investors have recently made changes to their positions in the stock. Provenance Wealth Advisors LLC bought a new position in shares of Perspective Therapeutics in the third quarter valued at approximately $44,000. Auctus Advisors LLC increased its stake in shares of Perspective Therapeutics by 83.6% during the third quarter. Auctus Advisors LLC now owns 37,359 shares of the company’s stock valued at $103,000 after acquiring an additional 17,015 shares during the period. Russell Investments Group Ltd. raised its holdings in Perspective Therapeutics by 53.1% during the third quarter. Russell Investments Group Ltd. now owns 61,012 shares of the company’s stock worth $168,000 after purchasing an additional 21,150 shares in the last quarter. Quantinno Capital Management LP bought a new stake in Perspective Therapeutics during the first quarter worth approximately $273,000. Finally, Taylor & Morgan Wealth Management LLC raised its holdings in Perspective Therapeutics by 127.6% during the second quarter. Taylor & Morgan Wealth Management LLC now owns 66,000 shares of the company’s stock worth $225,000 after purchasing an additional 37,000 shares in the last quarter. 54.66% of the stock is owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

(Get Free Report)

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company’s investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.

See Also

Insider Buying and Selling by Quarter for Perspective Therapeutics (NYSEAMERICAN:CATX)

Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.